The health sector had 21 companies reporting their quarterly earnings this week, with 18 of them beating profit estimates for the quarter. Quarter-To-Date, The Health Care Select Sector SPDR Fund ETF ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren. In this article, we are going to take a ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Your local pharmacy might be the next front in Donald Trump’s trade war. The president has in recent weeks promised to impose tariffs on all foreign-made medications, a move intended to encourage drug ...

Mounjaro brought in $3.5 billion in the period, while Zepbound added $1.9 billion to the tally, showing an advance on the $3.1 billion and $1.3 billion reported with the drugs in the third quarter ...

which is sold by Lilly as Mounjaro for diabetes and Zepbound for obesity, have actually been resolved, as reported earlier this month. Under US law, compounding pharmacies can make and sell patent ...

As the first earnings season of 2025 unfolds, investors are likely analyzing financial reports to refine their portfolio strategies.

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Major stock indexes closed higher on Friday, driven by corporate earnings reports from tech firms like Alphabet and Amazon.